Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.76 |
| ▸ | TTR | P02766 | 3/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.65 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.51 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036175 | 0.92 | PTGS2 (0.78) | PTGS2TTRCYP2C9USP2LMNA | |
| SCHEMBL23691079 | 0.88 | TTR (0.76) | PTGS2TTRCYP2C9USP2LMNA | |
| SCHEMBL1031733 | 0.86 | PTGS2 (1.00) | PTGS2TTRPTGS1ABCB11NR1I3 | |
| SCHEMBL6036587 | 0.86 | TTR (0.69) | PTGS2TTRCYP2C9USP2LMNA | |
| SCHEMBL13776395 | 0.85 | PTGS2 (0.53) | PTGS2TTRCYP2C9USP2LMNA | |
| Aceclofenac SCHEMBL29364020 | 0.84 | TTR (1.00) | PTGS2TTRCYP2C9USP2LMNA | |
| Aceclofenac SCHEMBL25734 | 0.84 | TTR (1.00) | PTGS2TTRCYP2C9USP2LMNA | |
| SCHEMBL6036412 | 0.84 | PTGS2 (0.59) | PTGS2TTRCYP2C9USP2LMNA | |
| SCHEMBL6036593 | 0.84 | PTGS2 (0.65) | PTGS2TTRCYP2C9USP2LMNA | |
| Aceclofenac SCHEMBL2905138 | 0.83 | TTR (0.97) | PTGS2TTRCYP2C9USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007505-B1 | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES | NOVARTIS AG (CH) | 2003-04-16 | — | — | EP | claimed |
| US-7115662-B2 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS AG (CH) | 2006-10-03 | — | — | US | disclosed |
| US-20040122254-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-6727281-B2 | SELECTIVE CYCLOOXYGENASE-2(COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-04-27 | — | — | US | disclosed |
| US-20020183391-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-12-05 | — | — | US | disclosed |
| US-6451858-B2 | FOR THERAPY OF INFLAMMATION, PYRESIS, PAIN, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, MIGRAINE HEADACHE, CANCER, MELANOMA, MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, OSTEOPOROSIS, ASTHMA, LUPUS AND PSORIASIS; SIDE EFFECT REDUCTION | NOVARTIS AG (CH) | 2002-09-17 | — | — | US | disclosed |
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-01-31 | — | — | US | disclosed |
| US-6310099-B1 | 5-METHYL OR ETHYL-2-(2-'CHLORO OR FLUORO OR TRIFLUROMETHYL-6'FLUORO OR CHLOROANILINO) PHENYLACETIC ACID OR SALT IS USED AS COX-2 SELECTIVE CYCLOOXYGENASE INHIBITOR | NOVARTIS AG (CH) | 2001-10-30 | — | — | US | disclosed |
| US-6291523-B1 | SELECTIVE COX-2 CYCLOOXYGENASE INHIBITORS | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | HCAR2, CYP2F1, CYP2E1 | PTGS2 5/4885TTR 4065/4885CYP2C9 37/4885 |
| US-20040122254-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | CYP2F1, CYP2E1, PTGER1 | PTGS2 8/4885TTR 3750/4885CYP2C9 21/4885 |
| US-20020183391-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | CYP2F1, CYP2E1, PTGER1 | PTGS2 8/4885TTR 3750/4885CYP2C9 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.